Skip to main navigation

Investor Relations

Investors & Media
Contact Us
Careers

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Press Coverage

Year

Apr 06, 2022

FDA approves BioXcel Therapeutics drug for agitation

Apr 06, 2022

Psych and neuro R&D notch a win as BioXcel gets FDA approval for schizophrenia, bipolar disorder-related agitation

Apr 06, 2022

A Win for AI: FDA Approves BioXCel Therapy for Bipolar Disorder & Schizophrenia

Feb 28, 2022

Sublingual Dexmedetomidine May Rapidly Calm Bipolar Agitation

Feb 23, 2022

Sublingual Dexmedetomidine Beneficial Against Severe Agitation in Bipolar Disorders: JAMA

Feb 23, 2022

BioXcel drug shows promise in reducing agitation in those with bipolar disorder

Feb 22, 2022

Sublingual Dexmedetomidine Reduces Agitation in Patients with Bipolar Disorder

Feb 22, 2022

BioXcel Agitation with Bipolar Drug Meets Primary and Secondary Endpoints in Phase 3

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 18 of 18

Site - Investor Tools

Print Page

Tear Sheet

Email Alerts

RSS Feeds

Contacts

Search

About Us
Our Products
Our Pipeline
Our Science
Patients & Advocacy

Investors & Media
Contact Us
Careers

Copyright © 2022 BioXcel Therapeutics, Inc. All Rights Reserved.

Privacy Policy
Disclaimer
Sitemap